Results 71 to 80 of about 26,607 (237)

Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol

Revista Brasileira de Hematologia e Hemoterapia
Acute promyelocytic leukemia has good prognosis in view of the high complete remission and survival rates achieved with therapies containing all-trans retinoic acid or arsenic trioxide.
Erick Crespo-Solis, Jorge Contreras-Cisneros, Roberta Demichelis-Gómez, Adriana Rosas-López, Juan Mauricio Vera-Zertuche, Alvaro Aguayo, Xavier López-Karpovitch   +6 more
doaj   +1 more source

Treatment of Acute Promyelocytic Leukemia

Hematology, 2006
AbstractCure of acute promyelocytic leukemia (APL) is now a possibility for most patients through the use of state-of-the-art treatments, which include simultaneous administration of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy for induction and consolidation, as well as ATRA-based maintenance. Risk-adapted strategies to modulate
openaire   +3 more sources

Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?

American Journal of Hematology, EarlyView.
Sudhir Tauro, Ayalew Tefferi
wiley   +1 more source

Herpes Simplex Virus Hepatitis: An Overlooked Cause of Acute Liver Failure Across a Broad Spectrum of Immunocompromise

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background and Aims Herpes simplex virus (HSV) infection is common worldwide, but hepatic involvement is rare. HSV hepatitis is an uncommon yet frequently catastrophic cause of acute hepatitis and acute liver failure (ALF), accounting for < 1% of ALF cases while carrying very high mortality when diagnosis and antiviral therapy are delayed ...
Mario U. Mondelli, Serena Ludovisi, Angela Di Matteo, Gülşen Özkaya Şahin, William Irving, European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source

Signaling through CD44 affects cell cycle progression and c-Jun expression in acute myeloid leukemia cells [PDF]

, 2004
We present here the first evidence linking CD44 signaling to c-Jun expression and cell cycle progression in myeloid cell line models. CD44 ligation with the anti-CD44 monoclonal antibodies have been shown to induce differentiation and inhibit the ...
Abdul Ali Peer Zada, Peer Zada, Abdul Ali   +1 more
core  

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Regulation of 92-kD gelatinase release in HL-60 leukemia cells [PDF]

, 1994
Matrix metalloproteinase 9 (MMP-9), also known as 92-kD type IV collagenase/gelatinase, is believed to play a critical role in tumor invasion and metastasis. Here, we report that MMP-9 was constitutively released from the human promyelocytic cell line HL-
Petrides, P. E., Kolb, H., Ries, Christian   +2 more
core  

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

, 2001
In acute myeloid leukemia (AML), further prognostic determinants are required in addition to cytogenetics to predict patients at increased risk of relapse.
Anthony H. Goldstone, Burnett, Alan Kenneth, Gale, RE, David C. Linch, Rosemary E. Gale, Stephen E. Langabeer, Belton, A.A, Georgina Harrison, Harrison, G, Gale, R.E., Bowen, D.T., Langabeer, S. E., Goldstone, A. H., Belton, AA, Keith Wheatley, Linch, DC, Frew, M. E., Wheatley, K., Bowen, DT, Walker, H., Goldstone, A.H., Wheatley, Keith, Marion E. Frew, Belton, A. A., Panagiotis D. Kottaridis, Langabeer, S.E., Alan K. Burnett, Helen Walker, Andrea A. Belton, Kottaridis, P. D., Walker, H, Kottaridis, P.D., Bowen, D. T., Burnett, AK, Burnett, A.K., Kottaridis, PD, David T. Bowen, Langabeer, SE, Frew, ME, Frew, M.E., Wheatley, K, Goldstone, AH, Gale, R. E., Linch, D. C., Harrison, G., Linch, D.C.   +45 more
core   +1 more source

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

American Journal of Hematology, Volume 101, Issue 6, Page 1407-1420, June 2026.
ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the ...
Nancy Gillis, Christelle Colin‐Leitzinger, Yi‐Han Tang, Michael Otterstatter, Seth Sherman, Ling Zhang, Lynn C. Moscinski, Mary Ellen Walker, Jeffrey S. Painter, Gregory A. Abel, Tareq Al Baghdadi, H. Joachim Deeg, James M. Foran, Steven D. Gore, Alexandra M. Harrington, Steven H. Kroft, Jane Jijun Liu, Wael Saber, Shamsuddin Virani, Rafael Bejar, R. Coleman Lindsley, Eric Padron, Matthew J. Walter, Rami Komrokji, Amy E. DeZern, Mikkael A. Sekeres   +25 more
wiley   +1 more source

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry

, 2011
Our knowledge about acute promyelocytic leukemia (APL) patients is mainly based on data from clinical trials, whereas population-based information is scarce.
S Lehmann, Derolf, A. R., M Höglund, S Deneberg, Antunovic, P, Juliusson, G, Stockelberg, D.,, Möllgård, L, Wennstrom, L., Wennström, L, A Ravn, P Antunovic, Ravn, A., Carlsson, L., Derolf, A Rangert, Wennstrom, L.,, Antunovic, P., Hoglund, M.,, Rangert Derolf, Å, Lehmann, S.,, Tidefelt, U, D Stockelberg, Carlsson, L, Hoglund, M., Antunovic, Petar,, A Wahlin, Carlsson, L.,, Lehmann, S, L Möllgård, G Juliusson, Å Rangert Derolf, Deneberg, S., Tidefelt, Ulf,, Höglund, Martin,, Stockelberg, D, Wahlin, A, Lund University., Juliusson, Gunnar, L Wennström, Mollgard, L., Derolf, A. Rangert, Juliusson, Gunnar,, Ravn, S, Ravn, A, Lehmann, S., Juliusson, G., Wennström, Lovisa,, Stockelberg, D., Wahlin, A., Tidefelt, U., Rangert Derolf, A.,, Lehmann, Sören, Mollgard, L.,, Deneberg, S, Höglund, M, Ravn, A.,, U Tidefelt, Wahlin, A.,, Wahlin, Anders,, Juliusson, G.,, Tidefelt, U.,, L Carlsson, Stockelberg, Dick,, Högberg, M, Deneberg, S.,   +64 more
core   +1 more source